EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions

Tapas Kumar Mohapatra, Reena Rani Nayak, Ankit Ganeshpurkar, Prashant Tiwari, Dileep Kumar iD

Ibrain · 2025-06 · 11 (2) · 162-184

DOI: 10.1002/ibra.12197 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Ibrain, online erschienen am 10.05.2025. Verfasst von Tapas Kumar Mohapatra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology Nityananda College of Pharmacy Seragarh Balasore Odisha India. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 213 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD), a neurodegenerative disease leading to dementia, lacks a single definitive diagnosis. While current medications only manage symptoms, the ideal treatment would restore cognition. Traditional therapies targeting beta‐amyloid haven't yielded significant results, while new approaches target tau protein tangles, protein degradation pathways, inflammation, and neurotrophic factor depletion. Autophagy, a cellular degradation and recycling process, has emerged as a crucial hallmark and contributor to the pathogenesis of AD. Notably, autophagy induction has emerged as a promising therapeutic approach, with inducers like celastrol and caudatin promoting the degradation of toxic protein aggregates. Additionally, innovative drug formulations, such as nanoparticles, are being explored for targeted drug delivery. Research is increasingly focusing on neuroinflammation and developing multi‐targeted drugs to address various aspects of AD, potentially leading to preventive strategies in the early stages. This review summarizes the current state and emerging trends in AD drug development.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseN‐methyl‐D aspartate receptorsneurofibrillary tanglespresenilinβ‐amyloid

Autor:innen und Institutionen

  • Department of Pharmacology Nityananda College of Pharmacy Seragarh Balasore Odisha India.
  • Department of Pharmaceutical Chemistry Nityananda College of Pharmacy Balasore Odisha India.
  • Department of Pharmaceutical Sciences Dr. Harisingh Gour Vishwavidyalaya (A Central University) Sagar Madhya Pradesh India.
  • Department of Pharmacology Dayanandasagar University Bangalore Karnataka India.
  • Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences Manipal Academy of Higher Educatio (MAHE) Manipal Karnataka India.

ORCID-Profile: Dileep Kumar

Zitieren

APA

Mohapatra, T. K., Nayak, R. R., Ganeshpurkar, A., Tiwari, P., & Kumar, D. (2025). Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions. Ibrain, 11(2), 162-184. https://doi.org/10.1002/ibra.12197

Vancouver

Mohapatra TK, Nayak RR, Ganeshpurkar A, Tiwari P, Kumar D. Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions. Ibrain. 2025;11(2):162-184. doi:10.1002/ibra.12197

BibTeX
@article{Mohapatra2025,
  author = {Mohapatra, Tapas Kumar and Nayak, Reena Rani and Ganeshpurkar, Ankit and Tiwari, Prashant and Kumar, Dileep},
  title = {Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions},
  journal = {Ibrain},
  year = {2025},
  volume = {11},
  number = {2},
  pages = {162--184},
  doi = {10.1002/ibra.12197}
}
Kostenlos starten →